申请人:Astellas Pharma Inc.
公开号:EP2065369A1
公开(公告)日:2009-06-03
[Object] To provide a compound which can be used for the treatment of a disease associated with fatty acid amide hydrolase (FAAH), particularly urinary frequency, urinary incontinence and/or overactive bladder.
[Means for solution] It is confirmed that a urea compound chemical-structurally characterized by having a piperidine or piperazine ring or a salt thereof has an excellent FAAH-inhibitory activity, and thus the present invention is completed. The urea compound or its pharmaceutically acceptable salt of the present invention can increase the effective bladder capacity and ameliorate the state of urinary frequency, and is therefore useful as an agent for treating urinary frequency, urinary incontinence and/or overactive bladder.
[目的]提供一种化合物,该化合物可用于治疗与脂肪酸酰胺水解酶(FAAH)相关的疾病,特别是尿频、尿失禁和/或膀胱过度活动症。
[解决方法]经证实,一种化学结构特征为具有哌啶或哌嗪环的脲化合物或其盐具有优异的 FAAH 抑制活性,因此本发明得以完成。本发明的脲化合物或其药学上可接受的盐可增加有效膀胱容量,改善尿频状态,因此可作为治疗尿频、尿失禁和/或膀胱过度活动症的药物。